Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
The Ascendis Pharma pipeline includes TransCon Growth Hormone, a program that has completed Phase 2 studies in adults and children with growth hormone deficiency. Ascendis Pharma has initiated the Phase 3 heiGHt Trial for once-weekly TransCon Growth Hormone in pediatric patients. Ascendis Pharma is also developing two additional rare disease product candidates, TransCon PTH and TransCon CNP. In addition to its internal programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its partners. These collaborations are with Sanofi in the field of diabetes and Roche Genentech in the field of ophthalmology.
Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California and has research and development facilities in Heidelberg, Germany and Copenhagen, Denmark.
Vision 20/20 Strategic Plan
Ascendis Pharma is working towards a number of long-term strategic goals, outlined in a plan called “Vision 20/20.” This plan reflects our mission to create best-in-class rare disease products that address unmet medical needs by utilizing TransCon technology to improve parent drugs with demonstrated clinical proof-of-concept. Learn More
Innovative Prodrug Technology
We are building a fully integrated, rare disease-focused biopharmaceutical company to create a diverse pipeline of clinically superior prodrugs generated by our proprietary technology platform.